Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Karvezide
Karvezide 150 mg/12.5 mg tablets. · Abschnitt 4.5 · PDF-Seite 6–7
HOS-089155 · Präparat HOS-083799
6
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T09:00:00Z · SHA-256 241301f791d734a0e88bdd7041102a9911b42458c430c2a9020b5dfbebaf383a · Passage 51310a74f30b964c7791524bf84074d7bc087b7392957520e24cde77e6580a84 · Zeichen 1715–2596 im Abschnitt
Wechselwirkungen · Karvezide
Karvezide 300 mg/12.5 mg tablets. · Abschnitt 4.5 · PDF-Seite 22–23
HOS-089199 · Präparat HOS-083799
22
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T09:00:00Z · SHA-256 241301f791d734a0e88bdd7041102a9911b42458c430c2a9020b5dfbebaf383a · Passage 3841af3357a6b556ffbe1ba585eac1e7bf20f0fc3570e5e588213cc0c4b3a13b · Zeichen 1717–2599 im Abschnitt
Wechselwirkungen · Karvezide
Karvezide 150 mg/12.5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 39–40
HOS-089235 · Präparat HOS-083799
39
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T09:00:00Z · SHA-256 241301f791d734a0e88bdd7041102a9911b42458c430c2a9020b5dfbebaf383a · Passage 9e66e50143ddafe6061884c102f65413737d52f3205579188f647249fcbe8333 · Zeichen 1716–2598 im Abschnitt
Wechselwirkungen · Karvezide
Karvezide 300 mg/12.5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 56–57
HOS-089271 · Präparat HOS-083799
56
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T09:00:00Z · SHA-256 241301f791d734a0e88bdd7041102a9911b42458c430c2a9020b5dfbebaf383a · Passage 83195e0cd4d511eab05753997ff2bbd7c960dbb026602da219877011f99a7496 · Zeichen 1716–2598 im Abschnitt
Wechselwirkungen · Karvezide
Karvezide 300 mg/25 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 73–74
HOS-089307 · Präparat HOS-083799
73
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T09:00:00Z · SHA-256 241301f791d734a0e88bdd7041102a9911b42458c430c2a9020b5dfbebaf383a · Passage 937c091f055b54da7788615b0a8f796eec0d3e70caa79330356844a077ae478c · Zeichen 1716–2598 im Abschnitt
Wechselwirkungen · CoAprovel
CoAprovel 150 mg/12.5 mg tablets. · Abschnitt 4.5 · PDF-Seite 6–7
HOS-089343 · Präparat HOS-083831
6
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T17:00:00Z · SHA-256 663294994546958f142b58235345414fc155e758fcd620182b00e348e98154c3 · Passage 51310a74f30b964c7791524bf84074d7bc087b7392957520e24cde77e6580a84 · Zeichen 1715–2596 im Abschnitt
Wechselwirkungen · CoAprovel
CoAprovel 300 mg/12.5 mg tablets. · Abschnitt 4.5 · PDF-Seite 22–23
HOS-089377 · Präparat HOS-083831
22
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T17:00:00Z · SHA-256 663294994546958f142b58235345414fc155e758fcd620182b00e348e98154c3 · Passage 3841af3357a6b556ffbe1ba585eac1e7bf20f0fc3570e5e588213cc0c4b3a13b · Zeichen 1717–2599 im Abschnitt
Wechselwirkungen · CoAprovel
CoAprovel 150 mg/12.5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 38–39
HOS-089412 · Präparat HOS-083831
38
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T17:00:00Z · SHA-256 663294994546958f142b58235345414fc155e758fcd620182b00e348e98154c3 · Passage 23798f26c1d10735ac1103845757c251001803747d2fddf0cb05a19068a26188 · Zeichen 1716–2598 im Abschnitt
Wechselwirkungen · CoAprovel
CoAprovel 300 mg/12.5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 55–56
HOS-089447 · Präparat HOS-083831
55
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T17:00:00Z · SHA-256 663294994546958f142b58235345414fc155e758fcd620182b00e348e98154c3 · Passage a26fad67a2ec8cdcb1ecacd438a628b3c48bc16decbc4fe714b306da0e88a2b6 · Zeichen 1716–2598 im Abschnitt
Wechselwirkungen · CoAprovel
CoAprovel 300 mg/25 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 72–73
HOS-089482 · Präparat HOS-083831
72
Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is
attenuated by the potassium-sparing effect of irbesartan. However, this effect of hydrochlorothiazide
on serum potassium would be expected to be potentiated by other medicinal products associated with
potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin,
carbenoxolone, penicillin G sodium). Conversely, based on the experience with the use of other
medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing
diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products
that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum
potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see
section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T17:00:00Z · SHA-256 663294994546958f142b58235345414fc155e758fcd620182b00e348e98154c3 · Passage c2b7f360d8b561f093a743dca5f3f4c2e65c52ad578491d1b450764778643626 · Zeichen 1716–2598 im Abschnitt
Wechselwirkungen · MicardisPlus
MicardisPlus 40 mg/12.5 mg tablets MicardisPlus 80 mg/12.5 mg tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-110352 · Präparat HOS-093371
Medicinal products associated with potassium loss and hypokalaemia (e.g. other kaliuretic diuretics,
laxatives, corticosteroids, ACTH, amphotericin, carbenoxolone, penicillin G sodium, salicylic acid and
derivatives)
If these substances are to be prescribed with the HCTZ-telmisartan combination, monitoring of
potassium plasma levels is advised. These medicinal products may potentiate the effect of HCTZ on
serum potassium (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): penicillin G sodium (HOS-089157) amphotericin (HOS-088524) salicylic acid (HOS-088803) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T09:30:00Z · SHA-256 33a880286f388c4977ad5f4024de04d276857e11506705f122fa64688952e4a1 · Passage 351acce8662fb5095fc81eec209fbb6adc8f78db89de853d6549affea80dec21 · Zeichen 497–940 im Abschnitt
Wechselwirkungen · MicardisPlus
MicardisPlus 80 mg/25 mg tablets · Abschnitt 4.5 · PDF-Seite 27
HOS-110431 · Präparat HOS-093371
Medicinal products associated with potassium loss and hypokalaemia (e.g. other kaliuretic diuretics,
laxatives, corticosteroids, ACTH, amphotericin, carbenoxolone, penicillin G sodium, salicylic acid and
derivatives)
If these substances are to be prescribed with the HCTZ-telmisartan combination, monitoring of
potassium plasma levels is advised. These medicinal products may potentiate the effect of HCTZ on
serum potassium (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): penicillin G sodium (HOS-089157) amphotericin (HOS-088524) salicylic acid (HOS-088803) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T09:30:00Z · SHA-256 33a880286f388c4977ad5f4024de04d276857e11506705f122fa64688952e4a1 · Passage 351acce8662fb5095fc81eec209fbb6adc8f78db89de853d6549affea80dec21 · Zeichen 497–940 im Abschnitt
Wechselwirkungen · Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop)
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-117971 · Präparat HOS-094733
Medicinal products affecting potassium
The potassium-depleting effect of hydrochlorothiazide is attenuated by the potassium-sparing effect of
irbesartan. However, this effect of hydrochlorothiazide on serum potassium would be expected to be
potentiated by other medicinal products associated with potassium loss and hypokalaemia (e.g. other
kaliuretic diuretics, laxatives, amphotericin, carbenoxolone, penicillin G sodium). Conversely, based
on the experience with the use of other medicinal products that blunt the renin-angiotensin system,
concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing
potassium or other medicinal products that may increase serum potassium levels (e.g. heparin sodium)
may lead to increases in serum potassium. Adequate monitoring of serum potassium in patients at risk
is recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-04T14:02:00Z · SHA-256 a042eb891ea2c5486827adad4aa2697b20f0615135f11f14a4bb7f7559935cbd · Passage d42a28efc9f65817ce0a5b7ff2f2c1e0ceca7ebe8d0f2de72b385403ecd5a3d0 · Zeichen 1805–2682 im Abschnitt
Wechselwirkungen · Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop)
Irbesartan Hydrochlorothiazide Zentiva 300 mg/12.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 24
HOS-118014 · Präparat HOS-094733
Medicinal products affecting potassium
The potassium-depleting effect of hydrochlorothiazide is attenuated by the potassium-sparing effect of
irbesartan. However, this effect of hydrochlorothiazide on serum potassium would be expected to be
potentiated by other medicinal products associated with potassium loss and hypokalaemia (e.g. other
kaliuretic diuretics, laxatives, amphotericin, carbenoxolone, penicillin G sodium). Conversely, based
on the experience with the use of other medicinal products that blunt the renin-angiotensin system,
concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing
potassium or other medicinal products that may increase serum potassium levels (e.g. heparin sodium)
may lead to increases in serum potassium. Adequate monitoring of serum potassium in patients at risk
is recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-04T14:02:00Z · SHA-256 a042eb891ea2c5486827adad4aa2697b20f0615135f11f14a4bb7f7559935cbd · Passage d42a28efc9f65817ce0a5b7ff2f2c1e0ceca7ebe8d0f2de72b385403ecd5a3d0 · Zeichen 1805–2682 im Abschnitt
Wechselwirkungen · Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop)
Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 41
HOS-118049 · Präparat HOS-094733
Medicinal products affecting potassium
The potassium-depleting effect of hydrochlorothiazide is attenuated by the potassium-sparing effect of
irbesartan. However, this effect of hydrochlorothiazide on serum potassium would be expected to be
potentiated by other medicinal products associated with potassium loss and hypokalaemia (e.g. other
kaliuretic diuretics, laxatives, amphotericin, carbenoxolone, penicillin G sodium). Conversely, based
on the experience with the use of other medicinal products that blunt the renin-angiotensin system,
concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing
potassium or other medicinal products that may increase serum potassium levels (e.g. heparin sodium)
may lead to increases in serum potassium. Adequate monitoring of serum potassium in patients at risk
is recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-04T14:02:00Z · SHA-256 a042eb891ea2c5486827adad4aa2697b20f0615135f11f14a4bb7f7559935cbd · Passage d42a28efc9f65817ce0a5b7ff2f2c1e0ceca7ebe8d0f2de72b385403ecd5a3d0 · Zeichen 1803–2680 im Abschnitt
Wechselwirkungen · Irbesartan/Hydrochlorothiazide Teva
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-211942 · Präparat HOS-154792
6
Medicinal products affecting potassium
The potassium-depleting effect of hydrochlorothiazide is attenuated by the potassium-sparing effect of
irbesartan. However, this effect of hydrochlorothiazide on serum potassium would be expected to be
potentiated by other medicinal products associated with potassium loss and hypokalaemia (e.g. other
kaliuretic diuretics, laxatives, amphotericin, carbenoxolone, penicillin G sodium). Conversely, based on the
experience with the use of other medicinal products that blunt the renin-angiotensin system, concomitant use
of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other
medicinal products that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in
serum potassium. Adequate monitoring of serum potassium in patients at risk is recommended (see section
4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-16T17:46:00Z · SHA-256 d153807aa78b933b85a74033d8ce9ad79fcd03f761c66d536fff8befc9ae2c26 · Passage cdc64f48a77dfbdb33ca88e48a310cdbb7fa9f1a2435cbb431d2e2d5e72de260 · Zeichen 1331–2211 im Abschnitt
Wechselwirkungen · Ifirmacombi
Ifirmacombi 150 mg/12.5 mg film-coated tablets Ifirmacombi 300 mg/12.5 mg film-coated tablets Ifirmacombi 300 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-125145 · Präparat HOS-096013
Medicinal products affecting potassium:
The potassium-depleting effect of hydrochlorothiazide is attenuated by the potassium-sparing effect of
irbesartan. However, this effect of hydrochlorothiazide on serum potassium would be expected to be
potentiated by other medicinal products associated with potassium loss and hypokalaemia (e.g. other
kaliuretic diuretics, laxatives, amphotericin, carbenoxolone, penicillin G sodium). Conversely, based
on the experience with the use of other medicinal products that blunt the renin-angiotensin system,
concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing
potassium or other medicinal products that may increase serum potassium levels (e.g. heparin sodium)
may lead to increases in serum potassium. Adequate monitoring of serum potassium in patients at risk
is recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): heparin sodium (HOS-089158) penicillin G sodium (HOS-089157) amphotericin (HOS-088524) lead (HOS-085592) potassium (HOS-086929) carbenoxolone (HOS-089156)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-16T11:57:00Z · SHA-256 de9ed4436066d5e17ee66d54836788a39065e3bc0f0ec088c02563c1958dcb02 · Passage 5ce77cadc381b0de543e4f8f2c973bfbdaec9c577c78524ea86a0099c022049e · Zeichen 1724–2602 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.